Personalized blood thinner during dialysis for kidney failure
Part of Digestive system, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new way to give a blood thinner during dialysis to people whose bodies cannot break it down normally. It aims to make dialysis safer and more comfortable for people with kidney and liver problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You have severe kidney problems (acute kidney injury or end-stage kidney disease) and need a special type of dialysis called CRRT.
- Your body cannot break down a blood thinner called citrate, often because of liver failure or very poor blood flow (septic shock).
- You must be able to get a stable access for dialysis (a large vein in your neck, chest, or leg).
- You must understand the study and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether a blood thinner called citrate is safe and effective in patients who have both kidney and liver failure while on continuous dialysis in the ICU. It may help guide treatment for people with serious organ problems.
This study compares different patterns of continuous kidney dialysis (called CRRT) to see how they affect calcium levels in the blood when using a citrate-based blood thinner. It may help find the safest way to manage calcium during treatment.
This Phase 3 study checks whether Prismocitrate 18 is safe for adults who need a kidney filtration treatment called CRRT. It is mainly for people who cannot safely use heparin (a common blood thinner) due to bleeding risk.
This study compares two blood-thinning medications used during continuous dialysis for acute kidney injury: one uses citrate (a chemical that prevents clotting) and the other uses heparin (a standard blood thinner). By looking at how well these treatments work, the study aims to find the safest and most effective way to keep the dialysis filter working.
This study tests whether a specific blood-thinning method using citrate works safely and effectively in critically ill patients whose kidneys have suddenly stopped working and need a special filtering machine. Researchers want to confirm that this approach prevents dangerous blood clots while keeping patients safe.
This study tests a special blood-filtering treatment for patients in the intensive care unit (ICU) with acute kidney injury. It uses a medicine called citrate to prevent blood clotting during dialysis, which may be safer for patients whose liver cannot process citrate normally.
Hear when a new CKD 5D, Hemodialysis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.